Malaria Information and Prophylaxis, by Country [M]

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Macau SAR (China) None Not Applicable Not Applicable Not Applicable
Macedonia None Not Applicable Not Applicable Not Applicable
Madagascar All areas, except rare cases in Antananarivo. Chloroquine Primarily P. falciparum. Less commonly,
P. ovale or P. vivax
All areas except Antananarivo: Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5.

Antananarivo: None (mosquito avoidance only.)6

Madeira Islands (Portugal) None Not Applicable Not Applicable Not Applicable
Malawi All Chloroquine Primarily P. falciparum. Less commonly
P. malariae, P. ovale, or P. vivax
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Malaysia No indigenous cases of human malaria since 2017; zoonotic transmission of simian malaria occurs in rural, forested areas. None in Georgetown, Kuala Lampur, and Penang State (includes Penang Island). Previously, chloroquine Primarily P. knowlesi.7
Previously, P. falciparum,
P. malariae,
P. ovale
, or P. vivax
Rural, forested areas: Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Maldives None Not Applicable Not Applicable Not Applicable
Mali All Chloroquine Primarily P. falciparum. Less commonly,
P. malariae, P. ovale, or P. vivax
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Malta None Not Applicable Not Applicable Not Applicable
Marshall Islands None Not Applicable Not Applicable Not Applicable
Martinique (France) None Not Applicable Not Applicable Not Applicable
Mauritania All areas except Dakhlet-Nouadhibou and Tiris-Zemour in the north Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Mauritius None Not Applicable Not Applicable Not Applicable
Mayotte (France) Rare cases Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax None (mosquito avoidance only)6
Mexico Present in Chiapas and southern part of Chihuahua.
Rare cases in Campeche, Durango, Nayarit, Quintana Roo, Sinaloa, Sonora, and Tabasco. No malaria along the United States-Mexico border.
None P. vivax 100% States of Chiapas and southern part of Chihuahua: Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, primaquine,5 or tafenoquine5. Other areas with malaria: None (mosquito avoidance only)6

 

 

Micronesia, Federated States of; Includes: Yap Islands, Pohnpei, Chuuk, and Kosrae None Not Applicable Not Applicable Not Applicable
Moldova None Not Applicable Not Applicable Not Applicable
Monaco None Not Applicable Not Applicable Not Applicable
Mongolia None Not Applicable Not Applicable Not Applicable
Montenegro None Not Applicable Not Applicable Not Applicable
Montserrat (U.K.) None Not Applicable Not Applicable Not Applicable
Morocco None Not Applicable Not Applicable Not Applicable
Mozambique All Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2.  Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources. Where proportions are not available, the primary species and less common species are identified.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Before prescribing primaquine or tafenoquine, patients must be screened for G6PD deficiency using a quantitative test.
6. Mosquito avoidance includes applying topical mosquito repellant, sleeping under an insecticide treated bed net, and wearing protective clothing (e.g., long pants and socks, long sleeve shirt). For additional details on mosquito avoidance, see: https://www.cdc.gov/malaria/travelers/index.html
7. P. knowlesi is a malaria species with a simian host (macaque). Human cases have been reported from most countries in Southeast Asia and are associated with activities in forest or forest-fringe areas. This species of malaria has no known resistance to antimalarials.